Copper complexes in the triple-negative breast cancer landscape: advances and opportunities.
- 1Laboratory of Genetics and Biotechnology, Institute of Biotechnology, Universidade Federal de Uberlândia, Patos de Minas, Minas Gerais, Brazil.
- 2Laboratory of Nanobiotechnology Prof. Dr. Luiz Ricardo Goulart Filho, Institute of Biotechnology, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.
Abstract
Triple-negative breast cancer (TNBC) is a subset of mammary tumors with heterogeneous biology, lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Patients generally exhibit an aggressive course, less favorable disease-specific outcomes, and a higher propensity for early recurrence, with chemotherapy remaining the primary systemic treatment eligible for all patients. In this sense, efforts are urgent to identify new effective compounds, aiming to increase disease-free and overall survival. Copper complexes have emerged as promising in oncology by regulating redox balance and modulating hallmarks such as proliferation, apoptosis, epithelial-mesenchymal transition, and angiogenesis. Furthermore, complexes containing copper tend to have low adverse effects. In TNBC, copper compounds may represent at least one component of a multi-action management strategy, being potentially effective against these tumors. The focus of this review is to provide information on TNBC biology and the role of copper in its signaling pathways, addressing the current copper complexes that have been explored to improve treatment.
Related
- Synthesis and Biological Activity of Iminophosphine Copper(I) Complexes Derived from 2-(Diphenylphosphino)benzaldehyde and 4-Substituted-Benzylamines
- Current Advances in Spatial Pathology of Nasal Polyps: Challenges, Opportunities for Artificial Intelligence, and Future Directions
- Reduced Schiff Base Copper(II) Complexes Derived from 2-, 3-, and 4-Methoxybenzylamine: DNA Binding and Cleavage, BSA Binding, Cytotoxic and SOD Mimetic Properties.
- Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer
- Personalized genomic landscape of prostate cancer in African American men reveals novel drivers and therapeutic opportunities
BibTeX
@article{lima2026copper,
title = {{Copper complexes in the triple-negative breast cancer landscape: advances and opportunities.}},
author = {Paula Marynella Alves Pereira Lima and André Carlos Pereira de Matos and Gabriela da Silva Guimarães and Laryssa Aparecida Sales Barbosa and Thaise Gonçalves Araújo},
journal = {Frontiers in molecular biosciences},
year = {2026},
month = oct,
doi = {10.3389/fmolb.2026.1931263},
url = {https://europepmc.org/article/MED/42928858},
note = {CC BY},
}
RIS
TY - JOUR
TI - Copper complexes in the triple-negative breast cancer landscape: advances and opportunities.
AU - Paula Marynella Alves Pereira Lima
AU - André Carlos Pereira de Matos
AU - Gabriela da Silva Guimarães
AU - Laryssa Aparecida Sales Barbosa
AU - Thaise Gonçalves Araújo
PY - 2026
DA - 2026/10/12
JO - Frontiers in molecular biosciences
DO - 10.3389/fmolb.2026.1931263
UR - https://europepmc.org/article/MED/42928858
AB - Triple-negative breast cancer (TNBC) is a subset of mammary tumors with heterogeneous biology, lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Patients generally exhibit an aggressive course, less favorable disease-specific outcomes, and a higher propensity for early recurrence, with chemotherapy remaining the primary systemic treatment eligible for all patients. In this sense, efforts are urgent to identify new effective compounds, aiming to increase disease-free and overall survival. Copper complexes have emerged as promising in oncology by regulating redox balance and modulating hallmarks such as proliferation, apoptosis, epithelial-mesenchymal transition, and angiogenesis. Furthermore, complexes containing copper tend to have low adverse effects. In TNBC, copper compounds may represent at least one component of a multi-action management strategy, being potentially effective against these tumors. The focus of this review is to provide information on TNBC biology and the role of copper in its signaling pathways, addressing the current copper complexes that have been explored to improve treatment.
SN - 2296-889X
ER -